Iduronidase
Sign in to saveAlso known as mucopolysaccharidosis type I, IDUA, α-L-iduronidase, alpha-L-iduronidase, human alpha-L-iduronidase, alpha-L-iduronidase precursor
chemische Verbindung
Key facts
- Drug.P
- 4
- Drug.DailyMedID
- Laronidase
- Drug.O
- 1261
- Drug.S
- 12
- Drug.pregnancy_AU
- B2
- Protein.Name
- iduronidase, α-L-
- Protein.HGNCid
- 5391
- Protein.Symbol
- IDUA
- Protein.EntrezGene
- 3425
- Protein.OMIM
- 252800
- Protein.RefSeq
- NM_000203
- Protein.UniProt
- P35475
- Protein.ECnumber
- 3.2.1.76
- Protein.Chromosome
- 4
- Protein.Arm
- p
- Protein.Band
- 16.3
- Drug.USAN
- Laronidase
- Drug.JAN
- Laronidase (genetical recombination)
via Wikipedia infobox
Chemical data
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Enzyme
- First approval
- 2003
- Admin. routes
- parenteral
- Indications
- Hurler syndrome, Hurler-Scheie syndrome, Scheie syndrome, mucopolysaccharidosis
via ChEMBL · EBI
Protein · UniProt
Alpha-L-iduronidase
- Gene
- IDUA
- Organism
- Homo sapiens (Human)
- Length
- 653 aa
- Molecular mass
- 72,670 Da
- Evidence
- 1: Evidence at protein level
Lysosomal hydrolase responsible for the degradation of the glycosaminoglycans heparan sulfate and dermatan sulfate
Swiss-Prot (reviewed) · via UniProt
Research
134 papers- Laronidase.2006
- Laronidase.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2002
- Enzyme replacement therapy with laronidase (Aldurazyme(®)) for treating mucopolysaccharidosis type I.The Cochrane database of systematic reviews · 2019
- Laronidase treatment of mucopolysaccharidosis I.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2005
- Laronidase for treating mucopolysaccharidosis type I.Genetics and molecular research : GMR · 2007
via PubMed
Clinical Trials
18 registered- ACTIVE_NOT_RECRUITINGEvaluation of Intravenous Laronidase Pharmacokinetics Before and After Hematopoietic Cell Transplantation in Patients With Mucopolysaccharidosis Type IH.Masonic Cancer Center, University of Minnesota · NCT05634512
- PHASE1TERMINATEDIntrathecal Enzyme Replacement Therapy for Spinal Cord Compression in Mucopolysaccharidosis (MPS) IPatricia I. Dickson, M.D. · NCT00215527
- PHASE3COMPLETEDStudy of Aldurazyme® Replacement Therapy in Patients With Mucopolysaccharidosis I (MPS I) DiseaseGenzyme, a Sanofi Company · NCT00258011
- PHASE4COMPLETEDChina Post-marketing Surveillance (PMS) Study of Aldurazyme®Genzyme, a Sanofi Company · NCT05134571
- COMPLETEDA Study to Assess the Safety of Myozyme® and of Aldurazyme® in Male and Female Participants of Any Age Group With Pompe Disease or With Mucopolysaccharidosis Type I (MPS I) in a Home-care SettingSanofi · NCT05073783
- TERMINATEDLaronidase (Aldurazyme TM) Enzyme Replacement Therapy With Hematopoietic Stem Cell Transplant for Hurler SyndromeMasonic Cancer Center, University of Minnesota · NCT01572636
Wikidata facts
- Instance of
- protein
- Has use
- medication
Show 6 more facts
- medical condition treated
- mucopolysaccharidosis I
- has characteristic
- biopharmaceutical
- legal status (medicine)
- boxed warning
- found in taxon
- Homo sapiens
- cell component
- extracellular exosome
- exact match
- purl.uniprot.org/uniprot/P35475
via Wikidata · CC0
Article · Deutsch
Iduronidase, genauer α-L-Iduronidase (IDUA) ist der Name für das Enzym, das in vielen Säugetieren L-Iduronat von Dermatansulfat und Heparansulfat abspaltet, den Hauptbestandteilen von Fasern und Knorpelgewebe im Körper. Es ist damit unverzichtbarer Bestandteil des Reaktionswegs, der diese Stoffe im Körper abbaut. Es wird in den Lysosomen aller Zellen gebildet. Mutationen am IDUA-Gen können Mangel an diesem Enzym und so beim Menschen verschiedene Typen der Mucopolysaccharidose verursachen.
Abstract from DBpedia / Wikipedia · CC BY-SA